TRPV1: a therapeutic target for novel analgesic drugs? - PubMed (original) (raw)
Review
. 2006 Nov;12(11):545-54.
doi: 10.1016/j.molmed.2006.09.001. Epub 2006 Sep 25.
Affiliations
- PMID: 16996800
- DOI: 10.1016/j.molmed.2006.09.001
Review
TRPV1: a therapeutic target for novel analgesic drugs?
Arpad Szallasi et al. Trends Mol Med. 2006 Nov.
Abstract
The vanilloid receptor TRPV1 is now recognized as a molecular integrator of painful stimuli ranging from noxious heat to endovanilloids in inflammation. Pharmacological blockade of TRPV1 represents a new strategy in pain relief. TRPV1 antagonists are expected to prevent pain by silencing receptors where pain is generated rather than stopping the propagation of pain, as most-traditional pain killers do. This hypothesis has already being tested in the clinic by administering small molecule TRPV1 antagonists (e.g. GlaxoSmithKline SB-705498) for migraine and dental pain. Paradoxically, in some murine models of chronic pain, TRPV1-deficient mice exhibit more pain-related behavior than their wild-type littermates, indicating that the understanding of TRPV1 in pain is still incomplete. Moreover, there is mounting evidence to suggest the existence of functional TRPV1 both in the brain and in various non-neuronal tissues. The biological role of these receptors remains elusive, but their tissue distribution clearly indicates that they are involved in many more functions than just pain perception. Here, we review the potential therapeutic indications and adverse effects of TRPV1 antagonists.
Similar articles
- Brain TRPV1: a depressing TR(i)P down memory lane?
Di Marzo V, Gobbi G, Szallasi A. Di Marzo V, et al. Trends Pharmacol Sci. 2008 Dec;29(12):594-600. doi: 10.1016/j.tips.2008.09.004. Epub 2008 Oct 22. Trends Pharmacol Sci. 2008. PMID: 18947889 - The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.
Szallasi A, Cortright DN, Blum CA, Eid SR. Szallasi A, et al. Nat Rev Drug Discov. 2007 May;6(5):357-72. doi: 10.1038/nrd2280. Nat Rev Drug Discov. 2007. PMID: 17464295 Review. - TRPV1 antagonists: the challenges for therapeutic targeting.
Khairatkar-Joshi N, Szallasi A. Khairatkar-Joshi N, et al. Trends Mol Med. 2009 Jan;15(1):14-22. doi: 10.1016/j.molmed.2008.11.004. Epub 2008 Dec 25. Trends Mol Med. 2009. PMID: 19097938 - Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons.
Niiyama Y, Kawamata T, Yamamoto J, Omote K, Namiki A. Niiyama Y, et al. Neuroscience. 2007 Aug 24;148(2):560-72. doi: 10.1016/j.neuroscience.2007.05.049. Epub 2007 Jul 25. Neuroscience. 2007. PMID: 17656027 - Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
Wong GY, Gavva NR. Wong GY, et al. Brain Res Rev. 2009 Apr;60(1):267-77. doi: 10.1016/j.brainresrev.2008.12.006. Epub 2008 Dec 25. Brain Res Rev. 2009. PMID: 19150372 Review.
Cited by
- 2-(4-Methylsulfonylaminophenyl) propanamide TRPV1 antagonists: Structure-activity relationships in the B and C-regions.
Sun W, Liu K, Ryu H, Kang DW, Kim YS, Kim MS, Cho Y, Bhondwe RS, Thorat SA, Kim HS, Pearce LV, Pavlyukovets VA, Tran R, Morgan MA, Lazar J, Ryder CB, Toth A, Blumberg PM, Lee J. Sun W, et al. Bioorg Med Chem. 2012 Feb 1;20(3):1310-8. doi: 10.1016/j.bmc.2011.12.014. Epub 2011 Dec 23. Bioorg Med Chem. 2012. PMID: 22227463 Free PMC article. - Novel Targets for Stroke Therapy: Special Focus on TRPC Channels and TRPC6.
Liu L, Gu L, Chen M, Zheng Y, Xiong X, Zhu S. Liu L, et al. Front Aging Neurosci. 2020 Mar 18;12:70. doi: 10.3389/fnagi.2020.00070. eCollection 2020. Front Aging Neurosci. 2020. PMID: 32256338 Free PMC article. Review. - Genes and primary headaches: discovering new potential therapeutic targets.
Rainero I, Rubino E, Paemeleire K, Gai A, Vacca A, De Martino P, Gentile S, Sarchielli P, Pinessi L. Rainero I, et al. J Headache Pain. 2013 Jul 12;14(1):61. doi: 10.1186/1129-2377-14-61. J Headache Pain. 2013. PMID: 23848401 Free PMC article. Review. - Imaging the influence of peripheral TRPV1-signaling on cerebral nociceptive processing applying fMRI-based graph theory in a resiniferatoxin rat model.
Wank I, Kutsche L, Kreitz S, Reeh P, Hess A. Wank I, et al. PLoS One. 2022 Apr 28;17(4):e0266669. doi: 10.1371/journal.pone.0266669. eCollection 2022. PLoS One. 2022. PMID: 35482725 Free PMC article. - Positive Allosteric Modulators of Glycine Receptors and Their Potential Use in Pain Therapies.
Gallagher CI, Ha DA, Harvey RJ, Vandenberg RJ. Gallagher CI, et al. Pharmacol Rev. 2022 Oct;74(4):933-961. doi: 10.1124/pharmrev.122.000583. Pharmacol Rev. 2022. PMID: 36779343 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical